Development of therapeutic antibodies against SIRPα

Cancer can evade detection by the immune system through interactions with effector cells such as macrophages. CD47 acts as a “don’t eat me” signal for normal cells and is overexpressed in many cancer types. CD47 interacts with SIRPα on macrophages and inhibits phagocytosis. Disrupting the CD47-SIRPα...

Full description

Saved in:
Bibliographic Details
Main Author: Chan, Lynn Xing Hui
Other Authors: Par Nordlund
Format: Final Year Project
Language:English
Published: 2017
Subjects:
Online Access:http://hdl.handle.net/10356/71532
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:Cancer can evade detection by the immune system through interactions with effector cells such as macrophages. CD47 acts as a “don’t eat me” signal for normal cells and is overexpressed in many cancer types. CD47 interacts with SIRPα on macrophages and inhibits phagocytosis. Disrupting the CD47-SIRPα signalling results in increased phagocytosis of cancerous cells. Most studies have so far focused on targeting CD47, however, its ubiquitous expression has raised concerns that such therapeutic agents could lead to unintended toxic effects. Also, the binding site of CD47 on SIRPα is a cryptic epitope, thus a small therapeutic agent is required to target it. To circumvent these issues, we focused on developing a small single VH domain antibody against SIRPα using a recombinant VH phage display library. Here, we have optimized biopanning strategies using different versions of SIRPα and different selection methods and have isolated a SIRPα binder that binds with low nanomolar affinity. The SIRPα binder identified through this research provides a functional basis for further modifications to improve its binding affinity with the ultimate aim of developing a therapeutic antibody against SIRPα.